<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02572609</url>
  </required_header>
  <id_info>
    <org_study_id>18.509</org_study_id>
    <nct_id>NCT02572609</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride</brief_title>
  <official_title>Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Brazil: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      to evaluate the bioavailability of ambroxol hydrochloride soft pastilles (test formulation),
      manufactured by Bolder Arzneimittel GmbH &amp; Co. KG to Boehringer Ingelheim compared to
      ambroxol hydrochloride syrup (Mucosolvan® adult syrup), manufactured by Boehringer Ingelheim
      do Brasil Química e Farmacêutica Ltda.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0:00h (hours), 0:15h, 0:30h, 0:45h, 1:00h, 1:15h, 1:30h, 1:45h, 2:00h, 2:20h, 2:40, 3:00, 3:30h, 4:00h, 5:00h, 6:00h, 8:00h, 12:00h, 16:00h, 24:00h, 36:00h and 48:00h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum plasma concentration achieved</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>0:00h (hours), 0:15h, 0:30h, 0:45h, 1:00h, 1:15h, 1:30h, 1:45h, 2:00h, 2:20h, 2:40, 3:00, 3:30h, 4:00h, 5:00h, 6:00h, 8:00h, 12:00h, 16:00h, 24:00h, 36:00h and 48:00h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration-time curve, calculated by the trapezoidal methods from time 0 to time t, where t is the time for the last concentration experimentally determined above the Limit of Quantification (LOQ).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Mucosolvan ® adult syrup</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ambroxol hydrochloride soft pastille</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ambroxol hydrochloride soft pastille</intervention_name>
    <arm_group_label>Ambroxol hydrochloride soft pastille</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mucosolvan ® adult syrup</intervention_name>
    <arm_group_label>Mucosolvan ® adult syrup</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  The volunteer is between 18 and 50 years old, is a man or a woman who is not pregnant
             and/or in breastfeeding regime, and undertakes to use effective birth control method
             throughout the study period.

          -  Body mass index higher than or equal to 18.5 and lower than or equal to 29.9 kg/m2.

          -  The volunteer is in good health status and is with no clinically significant
             diseases, at the discretion of the physician as Medical History, measurements of
             Blood Pressure, Pulse and Temperature, Physical Examination, Electrocardiogram and
             complementary Laboratory Tests.

          -  Volunteer able to understand the nature and objective of the study, including the
             risks and adverse effects, with the intention to cooperate with the investigator and
             act in accordance with the requirements of the entire trial, which has to be
             confirmed by signing the Informed Consent Form.

        Exclusion criteria:

          -  Volunteer has a known hypersensitivity to study drug or chemically related compounds;
             or to excipients described in adult syrup and/or soft pastille, for example, sorbitol
             (fructose).

          -  History or presence of gastrointestinal or liver diseases, or other condition that
             interferes with the absorption, distribution, excretion or metabolism of the drug.

          -  Use of maintenance therapy with any drug, except contraceptives.

          -  Diseases or health problems

          -  History of liver, renal, pulmonary, gastrointestinal, neurological, hematological,
             psychiatric, cardiac or allergic disease of any cause that requires pharmacological
             treatment or is considered to be clinically relevant by the investigator;

          -  Electrocardiographic findings not recommended, at the discretion of the investigator
             the participation in the study.

          -  Additional laboratory test results out of normal values according to the standard of
             this Potocol, unless they are considered clinically not significant by the
             investigator.

          -  Tabagism.

          -  Daily intake of more than 5 cups of coffee or tea.

          -  History of alcohol or drug abuse.

          -  Use of regular medication within 2 weeks prior to the initiation of this study, or
             use of any medication one week before starting this study.

          -  Hospitalization for any reason up to 8 weeks before starting the first treatment
             period of this study.

          -  Treatment within 3 months prior to this study treatment initiation with any drug that
             is known to have a well-defined toxic potential in large organs.

          -  Participation in any pharmacokinetic study with more than 300 mL of blood taken or
             ingested any - study drug within six months preceding the treatment start of this
             study.

          -  Donation or loss of 450 mL or more of blood within three months preceding the study
             or who donated more than 1500 mL within 12 months prior to this study treatment
             initiation.

          -  Pre-Confinement Examination Results

          -  Positive result for urine βHCG test carried out in female volunteers. Other
             conditions

          -  Any condition that prevents participation in the study as judged by the investigator.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 26, 2015</lastchanged_date>
  <firstreceived_date>October 5, 2015</firstreceived_date>
  <firstreceived_results_date>November 26, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ambroxol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The crossover design 2x2 was used in the study. This is a conventional nonreplicated design with two formulations, two periods, two sequences (RT and TR) where each individual is randomly allocated in one of these sequences.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence: TR</title>
          <description>01 pastille, single dose of Ambroxol hydrochloride soft pastille 15 mg (Test product) in period 1 and 2.5 mL, single dose, of Mucosolvan ® adult syrup (Reference product) in period 2.
Washout period: 7 days</description>
        </group>
        <group group_id="P2">
          <title>Sequence: RT</title>
          <description>2.5 mL, single dose, of Mucosolvan ® adult syrup (Reference product) in period 1 and 01 pastille, single dose, of Ambroxol hydrochloride soft pastille 15 mg (Test product) in period 2.
Washout period: 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1: Treatment Period 1 + Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2: Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set (TS): 36 subjects took 1 dose of reference product and 1 dose of test product.</population>
      <group_list>
        <group group_id="B1">
          <title>Sequence: TR</title>
          <description>01 pastille, single dose of Ambroxol hydrochloride soft pastille 15 mg (Test product) in period 1 and 2.5 mL, single dose, of Mucosolvan ® adult syrup (Reference product) in period 2.
Washout period: 7 days</description>
        </group>
        <group group_id="B2">
          <title>Sequence: RT</title>
          <description>2.5 mL, single dose, of Mucosolvan ® adult syrup (Reference product) in period 1 and 01 pastille, single dose, of Ambroxol hydrochloride soft pastille 15 mg (Test product) in period 2.
Washout period: 7 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="36"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29.39" spread="5.80"/>
                <measurement group_id="B2" value="31.22" spread="7.30"/>
                <measurement group_id="B3" value="30.30" spread="6.60"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="18"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="18"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>Maximum plasma concentration achieved</description>
        <time_frame>0:00h (hours), 0:15h, 0:30h, 0:45h, 1:00h, 1:15h, 1:30h, 1:45h, 2:00h, 2:20h, 2:40, 3:00, 3:30h, 4:00h, 5:00h, 6:00h, 8:00h, 12:00h, 16:00h, 24:00h, 36:00h and 48:00h</time_frame>
        <safety_issue>No</safety_issue>
        <population>The pharmacokinetic set (PK Set): 36 subjects provided 1 evaluable value of reference product and 1 evaluable value of test product for the primary PK endpoints (Cmax and AUC0-t) without important protocol violations with respect to the statistical evaluation of PK endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Mucosolvan ® Adult Syrup</title>
            <description>2.5 mL, single dose, of Mucosolvan ® adult syrup 6 mg/mL (Reference product).</description>
          </group>
          <group group_id="O2">
            <title>Ambroxol Hydrochloride Soft Pastille</title>
            <description>01 pastille, single dose of Ambroxol hydrochloride soft pastille 15 mg (Test product).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cmax</title>
            <description>Maximum plasma concentration achieved</description>
            <units>ng/mL</units>
            <param>Geometric Mean</param>
            <dispersion>Geometric Coefficient of Variation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="31.27" spread="30.38"/>
                  <measurement group_id="O2" value="35.50" spread="28.62"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Bioequivalence in the Cmax will be concluded if the 90% confidence interval for the test/reference ratio of the least squares means is fully contained within the acceptance range, 80.00% - 125.00%.</non_inferiority_desc>
            <p_value>0.0082</p_value>
            <method>Anderson-Hauck procedure</method>
            <param_type>T/R Ratio</param_type>
            <param_value>113.56</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>16.24</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>106.48</ci_lower_limit>
            <ci_upper_limit>121.10</ci_upper_limit>
            <estimate_desc>Standard Deviation is actually the Coefficient of variation intra subject (CVintra).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t</title>
        <description>Area under the plasma concentration-time curve, calculated by the trapezoidal methods from time 0 to time t, where t is the time for the last concentration experimentally determined above the Limit of Quantification (LOQ).</description>
        <time_frame>0:00h (hours), 0:15h, 0:30h, 0:45h, 1:00h, 1:15h, 1:30h, 1:45h, 2:00h, 2:20h, 2:40, 3:00, 3:30h, 4:00h, 5:00h, 6:00h, 8:00h, 12:00h, 16:00h, 24:00h, 36:00h and 48:00h</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Mucosolvan ® Adult Syrup</title>
            <description>2.5 mL, single dose, of Mucosolvan ® adult syrup 6 mg/mL (Reference product).</description>
          </group>
          <group group_id="O2">
            <title>Ambroxol Hydrochloride Soft Pastille</title>
            <description>01 pastille, single dose of Ambroxol hydrochloride soft pastille 15 mg (Test product).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUC0-t</title>
            <description>Area under the plasma concentration-time curve, calculated by the trapezoidal methods from time 0 to time t, where t is the time for the last concentration experimentally determined above the Limit of Quantification (LOQ).</description>
            <units>ng.h/mL</units>
            <param>Geometric Mean</param>
            <dispersion>Geometric Coefficient of Variation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="256.66" spread="33.36"/>
                  <measurement group_id="O2" value="307.00" spread="28.97"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Bioequivalence in the AUC0-t will be concluded if the 90% confidence interval for the test/reference ratio of the least squares means is fully contained within the acceptance range, 80.00% - 125.00%.</non_inferiority_desc>
            <p_value>0.0438</p_value>
            <method>Anderson-Hauck procedure</method>
            <param_type>T/R Ratio</param_type>
            <param_value>119.61</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>10.65</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>114.65</ci_lower_limit>
            <ci_upper_limit>124.79</ci_upper_limit>
            <estimate_desc>Standard Deviation is actually the Coefficient of variation intra subject (CVintra).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until 48 hours after last drug administration, upto 08 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mucosolvan® Adult Syrup</title>
        </group>
        <group group_id="E2">
          <title>Ambroxol Hydrochloride Soft Pastille</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
